Celyad Oncology SA Logo

Celyad Oncology SA

Clinical-stage biotech developing CAR T therapies for solid and blood cancers.

CYAD | BR

Overview

Corporate Details

ISIN(s):
BE0974260896 (+2 more)
LEI:
549300ORR0M8XF56OI64
Country:
Belgium
Address:
RUE ANDRE DUMONT 9, 1435 MONT-SAINT-GUIBERT
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Celyad Oncology SA is a clinical-stage biotechnology company that specializes in the discovery and development of Chimeric Antigen Receptor T-cell (CAR T) therapies for cancer treatment. The company focuses on pioneering advanced technologies to create a pipeline of both allogeneic (off-the-shelf) and autologous (patient-derived) CAR T-cell candidates. Celyad's differentiated strategy aims to broaden the range of treatable cancer indications, including hematological malignancies and solid tumors, while addressing the primary limitations of existing CAR T-cell therapies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-04 00:00
Declaration of Voting Results & Voting Rights Announcements
20250904_PR_Double-voting-rights.ENG_Website.pdf
English 154.5 KB
2025-09-04 00:00
Declaration of Voting Results & Voting Rights Announcements
20250904_PR_Double-droit-de-vote.FR_Website.pdf
French 91.2 KB
2025-08-26 08:30
Regulatory News Service
20250826_PR_R&D discontinuation ENG.FINAL.clean.pdf
English 176.9 KB
2025-08-26 08:30
Regulatory News Service
20250826_PR_Arret R&D FR.FINAL.pdf
French 162.6 KB
2025-08-13 00:00
Major Shareholding Notification
20250913_PR_Fortress Transparency Notification ENG.Final.pdf
English 238.9 KB
2025-08-13 00:00
Major Shareholding Notification
20250913_PR_Fortress Transparency Notification FR.Final.pdf
French 224.1 KB
2025-08-07 00:00
Declaration of Voting Results & Voting Rights Announcements
20250807 PR_Total Number of Voting Rights and Shares_ENG.3.pdf
English 106.6 KB
2025-08-07 00:00
Declaration of Voting Results & Voting Rights Announcements
20250807 PR_Total Number of Voting Rights and Shares_FR.2.pdf
French 110.9 KB
2025-08-07 00:00
Declaration of Voting Results & Voting Rights Announcements
20250807 PR_Total Number of Voting Rights and Shares_ENG.3.pdf
English 106.6 KB
2025-08-07 00:00
Declaration of Voting Results & Voting Rights Announcements
20250807 PR_Total Number of Voting Rights and Shares_FR.2.pdf
French 110.9 KB
2025-08-05 00:00
Post-Annual General Meeting Information
PV Notaire.5août2025.signed.pdf
French 334.3 KB
2025-08-05 00:00
Audit Report / Information
CELYAD_ Rapport de Commissaire - Augm de K 1 MEUR_VDEF_SIGNED_280725.pdf
French 150.8 KB
2025-08-05 00:00
Share Issue/Capital Change
FR_Celyad_Rapport Special du CA_PIPE2025_23juillet2025.FE.pdf
French 2.6 MB
2025-08-05 00:00
Share Issue/Capital Change
20250724_CYAD-PR-PIPE-ENG.2.pdf
English 113.4 KB
2025-08-05 00:00
Share Issue/Capital Change
20250724_CYAD-PR-PIPE-FR.2.pdf
French 86.4 KB

Automate Your Workflow. Get a real-time feed of all Celyad Oncology SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Celyad Oncology SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-11-28 Kane Matthew Board Other 1,035,714 279,642.78 EUR
2024-11-26 Piscitelli Dominic Board Other 10,000 2,700.00 EUR
2024-11-25 Iserentant Hannes Executive member Other 30,000 8,100.00 EUR
2024-11-22 Phan An Executive member Other 30,000 8,100.00 EUR
2024-11-06 Goblet Serge Board Other 10,000 2,700.00 EUR
2024-11-05 Udier Blagovic Marina Board Other 10,000 2,700.00 EUR

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.